MusclePharm (OTCMKTS:MSLP) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap consumer staples companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.
Earnings and Valuation
This table compares MusclePharm and Collegium Pharmaceutical’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|MusclePharm||$102.15 million||0.08||-$10.97 million||N/A||N/A|
|Collegium Pharmaceutical||$280.41 million||1.36||-$39.13 million||($1.19)||-9.60|
MusclePharm has higher earnings, but lower revenue than Collegium Pharmaceutical.
Institutional & Insider Ownership
27.8% of MusclePharm shares are owned by institutional investors. Comparatively, 92.1% of Collegium Pharmaceutical shares are owned by institutional investors. 60.7% of MusclePharm shares are owned by insiders. Comparatively, 8.1% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of current recommendations and price targets for MusclePharm and Collegium Pharmaceutical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Collegium Pharmaceutical has a consensus target price of $26.20, suggesting a potential upside of 129.42%. Given Collegium Pharmaceutical’s higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than MusclePharm.
This table compares MusclePharm and Collegium Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
MusclePharm has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.
MusclePharm beats Collegium Pharmaceutical on 6 of the 11 factors compared between the two stocks.
MusclePharm Corporation develops, manufactures, markets, and distributes nutritional supplements in the United States and internationally. It offers a range of powders, capsules, tablets, and gels. The company's MusclePharm brand product portfolio include Combat protein powder and Combat crunch protein bars; essentials supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products; and non-genetically modified organism sports performance products with organic ingredients, plant-based proteins, and natural caffeine sources for use in the various stages of the workout. It also provides FitMiss sports nutrition products, which are designed and formulated primarily for women lifestyle to cover various needs, including weight management, lean muscle mass, body composition, and general health and wellness. MusclePharm Corporation sells its products to various fitness enthusiasts, such as professional, combat sport, weight training, bodybuilding, running, and various team and individual sports, as well as individuals who lead an active lifestyle. The company was founded in 2006 and is headquartered in Burbank, California.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. The company offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. Furhter, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.